References
1. Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel.
Recommendations for the evaluation of risk and prophylaxis of tumour
lysis syndrome (TLS) in adults and children with malignant diseases: an
expert TLS panel consensus. Br. J. Haematol. 2010;149:578‑86.
2. Altman A. Acute tumor lysis syndrome. Semin. Oncol. 2001;28:3‑8.
3. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H,
Myint H, et al. Incidence, medical resource utilisation and costs of
hyperuricemia and tumour lysis syndrome in patients with acute leukaemia
and non-Hodgkin’s lymphoma in four European countries. Leuk. Lymphoma
2003;44:77‑83.
4. Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent
advances. Adv. Chronic Kidney Dis. 2014;21:18‑26.
5. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with
high-grade non-Hodgkin’s lymphoma. Am. J. Med. 1993;94:133‑9.
6. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et
al. Results of a randomized international study of high-risk central
nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia
in children and adolescents. Blood 2007;109:2736‑43.
7. Seidemann K, Meyer U, Jansen P, Yakisan E, Rieske K, Führer M, et al.
Impaired renal function and tumor lysis syndrome in pediatric patients
with Non-Hodgkin’s Lymphoma and B-ALL. Klin. Pädiatr. 1998;210:279‑84.
8. Stephanos K, Picard L. Pediatric Oncologic Emergencies. Emerg. Med.
Clin. North Am. 2018;36:527‑35.
9. Montesinos P, Lorenzo I, Martin G, Sanz J, Perez-Sirvent ML, Martinez
D, et al. Tumor lysis syndrome in patients with acute myeloid leukemia:
identification of risk factors and development of a predictive model.
Haematologica 2008;93:67‑74.
10. Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, et al.
FLORENCE: a randomized, double-blind, phase III pivotal study of
febuxostat versus allopurinol for the prevention of tumor lysis syndrome
(TLS) in patients with hematologic malignancies at intermediate to high
TLS risk. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015;26:2155‑61.
11. Yu X, Liu L, Nie X, Li J, Zhang J, Zhao L, et al. The optimal
single-dose regimen of rasburicase for management of tumour lysis
syndrome in children and adults: a systematic review and meta-analysis.
J. Clin. Pharm. Ther. 2017;42:18‑26.
12. Alakel N, Middeke JM, Schetelig J, Bornhäuser M. Prevention and
treatment of tumor lysis syndrome, and the efficacy and role of
rasburicase. OncoTargets Ther. 2017;10:597‑605.
13. McNeer JL, Nachman JB. The optimal use of steroids in paediatric
acute lymphoblastic leukaemia: no easy answers. Br. J. Haematol.
2010;149:638‑52.
14. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R,
et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in
Elderly Patients with Diffuse Large-B-Cell Lymphoma. N. Engl. J. Med.
2002;346:235‑42.
15. Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al.
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N. Engl. J.
Med. 2016;375:1044‑53.
16. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab:
Ongoing and future clinical development. Semin. Oncol. 2002;29:105‑12.
17. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. N. Engl.
J. Med. 1993;329:987‑94.
18. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic
strategies and classification. Br. J. Haematol. 2004;127:3‑11.
19. Chamuleau MED. Chamuleau MED, Stenner F, Chitu D, et al.
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed
high-risk Burkitt lymphoma: first results of a multi-center randomized
HOVON/SAKK trial. Presented at: 2022 EHA Congress; June 9-12, 2022;
Vienna, Austria. Abstract LB2370. 2022.
20. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N. Engl. J.
Med. 2011;364:1844‑54.
21. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et
al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for
Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III
Intergroup Trial Alliance/CALGB 50303. J. Clin. Oncol. 37:11.
22. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with
high-grade non-Hodgkin’s lymphoma. Am. J. Med. 1993;94:133‑9.
23. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P,
et al. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted
EPOCH-R in Adults With Untreated Burkitt Lymphoma. J. Clin. Oncol.
2020;38:2519‑29.
24. Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E,
Pacquement H, et al. Urate-oxidase in the prevention and treatment of
metabolic complications in patients with B-cell lymphoma and leukemia,
treated in the Société Française d’Oncologie PédiatriqueLMB89 protocol.
Ann. Oncol. 2002;13:789‑95.
25. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, et al.
Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the
Prevention and Treatment of Hyperuricemia During Induction Chemotherapy
of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe
d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult
Lymphoma) Study. J. Clin. Oncol. 2003;21:4402‑6.
26. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, et al.
Efficacy and safety of rasburicase, a recombinant urate oxidase
(ElitekTM), in the management of malignancy-associated
hyperuricemia in pediatric and adult patients: final results of a
multicenter compassionate use trial. Leukemia 2005;19:34‑8.
27. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al.
Rasburicase (recombinant urate oxidase) for the management of
hyperuricemia in patients with cancer: Report of an International
Compassionate Use Study. Cancer 2003;98:1048‑54.
28. Ribrag DV. Rituximab and dose-dense chemotherapy for adults with
Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial.
2016;387:10.
29. Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the
prevention and treatment of tumour lysis syndrome in children with
cancer. Cochrane Database Syst. Rev. [Internet] 2017 [cité 2023
avr 21];2017. Available from:
http://doi.wiley.com/10.1002/14651858.CD006945.pub4
30. Hyman CB, Sturgeon P. Prednison therapy of acute lymphatic leukemia
in children. Cancer 1956;9:965‑70.
31. Malpica L, Mufuka B, Galeotti J, Tan X, Grover N, Clark SM, et al. A
retrospective study on prephase therapy prior to definitive multiagent
chemotherapy in aggressive lymphomas. Leuk. Lymphoma 2020;61:1508‑11.
32. Pfreundschuh M. How I treat elderly patients with diffuse large
B-cell lymphoma. Blood 2010;116:5103‑10.
33. Lakshmaiah KC, Asati V, Babu K G, D L, Jacob LA, M C SB, et al. Role
of prephase treatment prior to definitive chemotherapy in patients with
diffuse large B-cell lymphoma. Eur. J. Haematol. 2018;100:644‑8.
34. Cui Y, Li X, Sun Z, Leng C, Young K, Wu X, et al. Safety and
efficacy of low-dose pre-phase before conventional-dose chemotherapy for
ulcerative gastric diffuse large B-cell lymphoma. Leuk. Lymphoma
2015;56:2613‑8.
35. Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, et al.
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell
lymphomas in patients aged 80 years or older: an open-label,
multicentre, single-arm, phase 2 trial from the LYSA group. Lancet
Haematol. 2017;4:e46‑55.
36. Paul F, Cartron G. Infusion-related reactions to rituximab:
frequency, mechanisms and predictors. Expert Rev. Clin. Immunol.
2019;15:383‑9.
37. Amitai I, Gafter‐Gvili A, Shargian‐Alon L, Raanani P, Gurion R.
Obinutuzumab‐related adverse events: A systematic review and
meta‐analysis. Hematol. Oncol. 2021;39:215‑21.
38. Courville J, Nastoupil L, Kaila N, Kelton J, Zhang J, Alcasid A, et
al. Factors Influencing Infusion-Related Reactions Following Dosing of
Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs
2021;35:459‑68.
39. Hayama T, Miura K, Uchiike A, Nakagawa M, Tsutsumi D, Sakagami M, et
al. A clinical prediction model for infusion-related reactions to
rituximab in patients with B cell lymphomas. Int. J. Clin. Pharm.
2017;39:380‑5.
40. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P,
Iacoboni G, et al. Glofitamab for Relapsed or Refractory Diffuse Large
B-Cell Lymphoma. N. Engl. J. Med. 2022;387:2220‑31.
41. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline
S, et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic
Lymphocytic Leukemia. N. Engl. J. Med. 2018;378:1107‑20.